Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Scientists discover link between common medications and serious falls in older men

  • Sleepy fruitflies get mellow

  • Research grasps how brain plans gripping motion

  • How to digitally stoke that old-time auction fever

  • Autism costs estimated to reach nearly 0 billion, potentially trillion, by 2025

  • Coffee consumption habits impact the risk of mild cognitive impairment

  • Very early birth linked to introversion, neuroticism, risk aversion in adulthood

  • Where memory is encoded and retrieved: New findings in a long-standing debate

  • Neurology researchers evaluate evidence base for tests for clinical cognitive assessment

  • Majority rule: Why conformity can actually be a good thing

  •